© 2020 MJH Life Sciences and Cure Today. All rights reserved.
© 2020 MJH Life Sciences™ and Cure Today. All rights reserved.
June 21st 2020, 6:00pm
June 15th 2020, 5:00pm
May 29th 2020, 11:52pm
The Food and Drug Administration approved the combination of Tecentriq and Avastin in patients with unresectable or metastatic hepatocellular carcinoma, making it the first immunotherapy regimen to be approved for this cancer type.
May 24th 2020, 6:00pm
In the spring 2020 issue of CURE®, Editor-in-Chief Dr. Debu Tripathy details how preventing liver cancer starts with understanding the precursors to cancer’s development.
May 11th 2020, 10:38pm
Nonalcoholic fatty liver disease can lead to cancer. Patients can reverse the damage through diet and exercise, but how can they know if they have the common condition?
May 5th 2020, 10:00pm
The Food and Drug Administration’s recent approval of Pemazyre (pemigatinib) is a ‘huge milestone’ for patients with cholangiocarcinoma, according to the advocacy coordinator with the Cholangiocarcinoma Foundation.
May 2nd 2020, 1:00am
Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for April 2020.
April 30th 2020, 1:04am
A gastrointestinal malignancy expert discusses the role genomics play in cholangiocarcinoma, as well as how genetic profiling may identify which treatment is best for patients.
April 18th 2020, 4:18am
The Food and Drug Administration approved Pemazyre for the treatment of patients with previously treated, advanced cholangiocarcinoma.
April 15th 2020, 1:08am
Although the new coronavirus has led to a delay in some cholangiocarcinoma trials, experts don’t expect the trials to come to an end.